MedGenome Launches OncoTrack MRD Test to Detect Relapse
Bengaluru-based genomics diagnostics company MedGenome has introduced OncoTrack MRD, a novel molecular residual disease test designed to detect cancer relapse early. Consequently, this liquid biopsy platform provides oncologists with a powerful molecular surveillance tool for patients who completed curative-intent therapy.
How the Molecular Residual Disease Test Works
Specifically, the platform uses a tumor-informed approach tailored to each individual patient. Clinicians first collect baseline tumor tissue along with matched peripheral blood during surgical resection. Next, genomic sequencing identifies patient-specific somatic alterations within the primary neoplasm. The laboratory then synthesizes a customized assay targeting these distinct variants. Therefore, subsequent monitoring requires only a routine peripheral blood draw. Furthermore, ultra-sensitive next-generation sequencing tracks circulating tumor DNA with exceptional precision. As a result, oncologists can identify microscopic residual disease months before conventional imaging reveals anatomical recurrence.
Clinical Utility and Longitudinal Cancer Surveillance
Early identification of disease relapse represents a critical priority in oncology care across India. In fact, conventional radiological modalities often fail to detect minimal cellular clones following surgery or adjuvant chemotherapy. However, serial ctDNA assessment enables doctors to track therapeutic response in real time. Clinicians can perform this blood test multiple times annually throughout survivorship. Thus, persistent ctDNA positivity flags high-risk patients who require proactive clinical reassessment or treatment intensification. Conversely, sustained ctDNA clearance reassures clinicians and patients regarding treatment efficacy. In addition, convenient nationwide home sample collection significantly reduces logistical barriers for cancer survivors.
Frequently Asked Questions
Q1: What is the primary clinical goal of OncoTrack MRD?
The test detects microscopic residual cancer cells and circulating tumor DNA after curative therapy, identifying recurrence long before standard imaging scans.
Q2: Why does this test require baseline tumor tissue?
Because it is a tumor-informed assay, scientists first sequence the original tumor tissue to identify patient-specific mutations for personalized longitudinal monitoring.
Q3: How often can oncologists repeat the blood test?
Clinicians can repeat the test multiple times each year to track molecular response and monitor cancer recurrence risk over time.
Enhancing Your Practice
For medical professionals looking to stay ahead in cancer diagnostics and patient care, exploring comprehensive oncology speciality courses can provide deeper clinical insights and advanced knowledge.
References
- MedGenome launches personalised blood test to detect and monitor cancer relapse - ETHealthworld
- MedGenome Labs. OncoTrack MRD Test (Molecular Residual Disease). Diagnostics MedGenome, 2026.
- Circulating tumour DNA-based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis. EBioMedicine, 2024.
